OserLab @DanaFarber @harvardmed Seeks To Identify New Targeted Therapies For Small Cell Lung Cancer. Tweets/Views are my own.
Boston, MA
Joined November 2019
- Tweets134
- Following220
- Followers527
- Likes558
OserLab retweeted
EED helps small cell lung cancer keep its neuroendocrine state by repressing lung adenocarcinoma genes: doi.org/10.1172/JCI199454
Matthew G. Oser @oser_lab & team @danafarber & @BrighamWomens report the polycomb scaffolding subunit EED as a key supporter of small-cell lung cancer neuroendocrine identity and EGFR-mutant lung adenocarcinoma-to-small-cell lung cancer transformation. Notably, inactivation of EED in mice impaired small cell lung cancer tumorigenesis.
The figure: EED inactivation promotes a shift from SCLC toward LUAD histology in an RPR2 GEMM in vivo.
@the_asci
#LungCancer #SCLC
Excited to share another new study from our lab, co-led by Keita Masuzawa and Kevin Dong: “A HUWE1 Regulatory Helix Gates ASCL1 Degradation Through Its C-Terminal Phospho-Degron in Small Cell Lung Cancer.”
genesdev.cshlp.org/content/e…
In this work, we combine genome-wide CRISPR knockout screening with base editor screening to identify regulators of ASCL1 protein abundance in SCLC and uncover a mechanism by which HUWE1 controls ASCL1 degradation through its C-terminal phospho-degron.
Excited to share new work from our lab: “Polycomb Scaffolding Subunit EED Supports the SCLC Neuroendocrine Identity and EGFR-Mutant LUAD to SCLC Transformation.”
jci.org/articles/view/199454
This study was led by our fabulous postdoctoral fellow Yixiang Li, who drove the mouse modeling, wet-lab experiments, and bioinformatic analyses-a true tour de force! Yixiang is a K99 awardee and is currently on the faculty job market. He is an exceptionally talented!
Congratulations to Yixiang and everyone involved in this work and thank you to our funding sources @AmericanCancer.
OserLab retweeted
🚨We're growing! Our lab at @TischCancer is #recruiting postdocs for 3 fully funded NIH projects. If you want to explore the biology of tumor dormancy, join us!!! Projects focus on:🧠Cancer neuroscience, ECM-driven dormancy, HER2 biology.
📩 email for more info or send your CV👇
Dear Colleagues,
In two weeks, I’ll ride the Pan-Mass Challenge (162 miles) for the second year in honor of my parents and everyone affected by cancer.100% of every donation supports cancer research at DFCI. Please consider donating. Thank you in advance!
profile.pmc.org/pmc/MO0250
OserLab retweeted
10th Anniversary!! of #SCLC U24 NCI Consortium meeting at @theNCI with @charlesrudin @PTRUJH Dr. John Minna Dr. Trudy Oliver @UTMDAnderson #SCLC #LCSM @UTSWCancerBio @NIH #plasticity #PDXs #SCLCsubtypes @SageJulien
Excited to share our latest preprint, a wonderful collaboration w/ Matt Freedman and Sylvan Baca’s labs. Leveraging cfChIP-seq from patient plasma + functional mouse modeling, we uncover how TF subtype shapes response and resistance to tarlatamab in SCLC.
biorxiv.org/content/10.64898…
Our latest collaboration with #MattFreedman and @Oser_Lab on resistance to tarlatamab: biorxiv.org/content/10.64898…. An exciting framework for studying cancer resistance: observations from patients using epigenomic #LiquidBiopsy -> functional validation in mouse models.
It was wonderful visiting the Northwestern BMG Department today and learning about all the outstanding science going on here. Thank you @LuWangLab for the invitation!
Join us today for the BMG Seminar Speaker Dr. Matthew Oser! @Oser_Lab Hosted by Dr. Lu Wang @LuWangLab #epigenetics #Cancer #LungCancer @NUFeinbergMed @NorthwesternMed @DanaFarber @harvardmed
Excited to share our new work in Dev Cell (authors.elsevier.com/a/1lg4l…), led by my highly talented postdoc Deli Hong! We find that loss of NOTCH2 creates a dependency on TRIM28, highlighting TRIM28 as a potential therapeutic target in NOTCH2-deficient or low-NOTCH2 SCLC.
Grateful to all of our collaborators including @yejingge at MDACC.
sciencedirect.com/science/ar…
Thrilled to share our new work published in Nature (rdcu.be/eBCM0). We report an exciting new potential therapeutic strategy with a fascinating mechanism of action for cancers with a compromised G1–S cell cycle checkpoint, including SCLC.
nature.com/articles/s41586-0…
This study was led by my highly talented postdoctoral fellow Shilpa Singh and was an outstanding collaboration with Circle Pharma and Deepak Nijhawan's lab at UTSW. @DanaFarberNews @DFarberThoracic.
OserLab retweeted
🧩 New paper out in Nature Communications!
"Unveiling the hidden interactome of CRBN molecular glues"
Huge thanks to our incredible team and collaborators who made this possible!
📖 Read the full open-access article here: nature.com/articles/s41467-0…
This is the first year I’m riding the Pan Mass Challenge in 2 weeks! I’m riding in honor of both my parents. It will be a deeply meaningful ride for me. All proceeds go toward cancer research at Dana Farber. Please donate if you can (details/link below) profile.pmc.org/MO0250